Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IMPOWER-QoL: IMPact Of Discontinuing Premedication for WEekly Paclitaxel on bReast Cancer Patients' Quality Of Life

NCT07478315 is registered in ClinicalTrials.gov with Charles LeMoyne Hospital as lead sponsor.

NCT NCT07478315
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07478315 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IMPOWER-QoL: IMPact Of Discontinuing Premedication for WEekly Paclitaxel on bReast Cancer Patients' Quality Of Life
Lead sponsor
Charles LeMoyne Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
March 15, 2026
Completion date
December 31, 2026
Enrollment
50 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer